Stem cell mystery: why some liver patients Don't get better
NCT ID NCT07198854
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study reviews medical records of 446 people with hepatitis B-related liver failure who received stem cell therapy. Researchers want to find out why some patients did not improve. The goal is to identify factors that affect treatment success so future patients can benefit more.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 446 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2025
- Expected to finish
-
Jun 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
HBV related-ACLF patients treated with MSCs at the Third Affiliated Hospital of Sun Yat-sen University from January 2010 to October 2018.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Clinical diagnosis of acute-on-chronic liver failure; Positive serum HBV surface antigen for more than 6 months; Received MSCs infusion more than one time. Exclusion Criteria: * Systemic or local malignancy; Hepatitis C virus infection; HIV infection or other immunodeficiency disease; Marked organ dysfunction (e.g., renal dysfunction); Pregnancy or lactation; Hyperthyroidism or other primary thyroid diseases; Incomplete data or lost to follow-up; Hospital stay \< 1 day.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Acute-on-chronic liver failure are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Third Affiliated Hospital of Sun Yat-sen University
RECRUITINGGuangzhou, Guangdong, 510630, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug combo calm immune overreaction and help the liver regrow in severe alcoholic hepatitis?
- Experimental injection aims to combat Life-Threatening liver failure
- Blood transfusion strategy could be refined for liver patients
- Could stem cells offer a lifeline for sudden liver failure?
- New device aims to filter toxins in liver crisis
- New device aims to filter toxic iron from blood in liver failure patients